Literature DB >> 11754110

Mutation rate of MAP2K4/MKK4 in breast carcinoma.

Gloria H Su1, Jason J Song, Elizabeth A Repasky, Mieke Schutte, Scott E Kern.   

Abstract

The stress-activated protein kinase (SAPK) pathways represent phosphorylation cascades that convey pro-apoptotic signals. The relevant inputs include Ras proteins as well as exposure of cells to ultraviolet light, tumor-necrosis factor, and other stress-related inputs. The mitogen-activated protein kinase kinase (MAPKK) homolog MAP2K4 (MKK4, SEK, JNKK1) is a centrally-placed mediator of the SAPK pathways. MAP2K4 mutations or homozygous deletions are reported in about 5% of a wide variety of tumor types. The exception is breast cancer, where genetic inactivation in 3 of 22 (15%) cell lines had suggested that the mutational involvement of MAP2K4 might be accentuated in this tumor type. This finding might have represented an important difference, or solely a chance numerical variation. To address this question, we studied an independent panel of 20 breast cancer cell lines and xenografts for MAP2K4 alterations. We found a splice acceptor mutation accompanied by loss of the other allele in the cell line MPE600. This was the sole alteration in this panel (5% of tumors). These data seem to re-establish a rather consistent rate of genetic inactivation of MAP2K4 among most tumor types, including breast cancer. The genetic evaluation of other mediators of the SAPK pathways might offer insight into a promising, but as yet poorly defined, tumor-suppressive system. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11754110     DOI: 10.1002/humu.9002

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  27 in total

1.  Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models.

Authors:  Colin Walsh; Isabelle Tanjoni; Sean Uryu; Alok Tomar; Ju-Ock Nam; Hong Luo; Angelica Phillips; Neela Patel; Cheni Kwok; Gerald McMahon; Dwayne G Stupack; David D Schlaepfer
Journal:  Cancer Biol Ther       Date:  2010-05-15       Impact factor: 4.742

2.  Non-cell-autonomous induction of tissue overgrowth by JNK/Ras cooperation in a Drosophila tumor model.

Authors:  Mirka Uhlirova; Heinrich Jasper; Dirk Bohmann
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-06       Impact factor: 11.205

Review 3.  The c-jun kinase/stress-activated pathway: regulation, function and role in human disease.

Authors:  Gary L Johnson; Kazuhiro Nakamura
Journal:  Biochim Biophys Acta       Date:  2007-01-04

4.  A kinase shRNA screen links LATS2 and the pRB tumor suppressor.

Authors:  Katrin Tschöp; Andrew R Conery; Larisa Litovchick; James A Decaprio; Jeffrey Settleman; Ed Harlow; Nicholas Dyson
Journal:  Genes Dev       Date:  2011-04-15       Impact factor: 11.361

5.  MicroRNA-802 plays a tumour suppressive role in tongue squamous cell carcinoma through directly targeting MAP2K4.

Authors:  Xiaozhen Wu; Zuode Gong; Lanying Sun; Long Ma; Qibao Wang
Journal:  Cell Prolif       Date:  2017-03-20       Impact factor: 6.831

Review 6.  JNK signalling in cancer: in need of new, smarter therapeutic targets.

Authors:  Concetta Bubici; Salvatore Papa
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

7.  Suppression of Ras-stimulated transformation by the JNK signal transduction pathway.

Authors:  Norman J Kennedy; Hayla K Sluss; Stephen N Jones; Dafna Bar-Sagi; Richard A Flavell; Roger J Davis
Journal:  Genes Dev       Date:  2003-03-01       Impact factor: 11.361

8.  A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma.

Authors:  Vincent W Keng; Augusto Villanueva; Derek Y Chiang; Adam J Dupuy; Barbara J Ryan; Ilze Matise; Kevin A T Silverstein; Aaron Sarver; Timothy K Starr; Keiko Akagi; Lino Tessarollo; Lara S Collier; Scott Powers; Scott W Lowe; Nancy A Jenkins; Neal G Copeland; Josep M Llovet; David A Largaespada
Journal:  Nat Biotechnol       Date:  2009-02-22       Impact factor: 54.908

9.  Role of JNK in a Trp53-dependent mouse model of breast cancer.

Authors:  Cristina Cellurale; Claire R Weston; Judith Reilly; David S Garlick; D Joseph Jerry; Hayla K Sluss; Roger J Davis
Journal:  PLoS One       Date:  2010-08-30       Impact factor: 3.240

10.  Association of genetic variation in mitotic kinases with breast cancer risk.

Authors:  Xianshu Wang; Zachary S Fredericksen; Robert A Vierkant; Matthew L Kosel; V Shane Pankratz; James R Cerhan; Christina Justenhoven; Hiltrud Brauch; Janet E Olson; Fergus J Couch
Journal:  Breast Cancer Res Treat       Date:  2009-04-30       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.